



Contents lists available at ScienceDirect

Trends in Cardiovascular Medicine

journal homepage: www.elsevier.com/locate/tcm

Editorial commentary: Wanted: MicroRNAs to the aid of the diabetic foot

Louise T. Dalgaard, MSc, PhD^{a,*}, Eugenia Carvalho, PhD^{b,c,d}

^a Department of Science and Environment, Roskilde University, Universitetsvej 1, DK-4000 Roskilde, Denmark

^b Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal

^c Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, United States

^d Arkansas Children's Research Institute, Little Rock, AR, United States

ARTICLE INFO

Keywords:

MicroRNA

Wound healing

Diabetic foot ulcer

Inflammation

Diabetes mellitus

Wound healing is complex and involves several interconnected phases, including hemostasis, inflammation, proliferation, maturation and remodeling [1]. Healthy skin is crucial for human body integrity. It is the largest organ system of the body, protecting against mechanical forces, fluid imbalance, thermal dysregulation and infections [2]. Over time, diabetes induces critical alterations in the skin, including imbalances in the wound healing phases [1]. In normal skin injury, acute inflammatory responses are initiated, beginning with recruitment of neutrophils, monocytes, and mast cells to the site of injury. Besides significant alteration in expression of inflammatory cytokines, such as TNF- α , IL-6, IL-8 and growth factors coordinating wound repair [3], diabetes can also cause alterations in skin insulin action, crucial for maintenance of glucose and lipid homeostasis [4]. In contrast to healthy acute wounds, wound healing in diabetic patients does not progress correctly due to peripheral neuropathy, macro- and micro-vascular disease, impaired angiogenesis and chronic inflammation often with persistent infection [5–9]. Controlling skin inflammation improves diabetic wound healing [3,7,10–12].

Diabetes worldwide has assumed epidemic proportions with over 650 million diabetics predicted by 2040 [13–15]. Diabetic foot ulceration (DFU) is a severe complication occurring in about 20% of diabetes patients, requiring intensive care, often resulting in hospitalizations and even amputations for its management, thus it represents a serious public health problem. Moreover, about 58% of clinically treated ulcers are infected, and the progression from DFU

to diabetic foot infection is present in 85% of amputation cases [16] highlighting the importance of integrated treatments [17,18]. The cost of treatment in the US in 2001 was about 11 billion dollars [19]. Importantly, if multidisciplinary treatments are implemented, amputations can be decreased by 49–85% [18,20]. Therefore, development of an effective treatment for chronic DFU is imperative.

Neuropathy and/or diminished vascular perfusion are serious risk factors for DFU development. However, infection control is difficult due to diminished local blood flow, and systemic antibiotics may not reach infected ulcers in suitable concentrations. Local anti-infection or immune-modulatory treatments constitute an important, yet underutilized, strategy for treatment of diabetic wounds.

In this issue of the Journal, Ozdemir and Feinberg [21] present a comprehensive review on the pathophysiological roles of microRNAs (miRNA) in diabetic wound healing and describe opportunities for their therapeutic use. In brief, miRNAs are small non-coding RNA molecules controlling protein levels by post-transcriptional action [22–24]. Recently, miRNAs have been recognized as important regulators of glucose metabolism [25], and their altered expression and function has been linked to loss of glucose homeostasis, leading to pathogenic conditions, including diabetes [25]. They are also important players in wound healing under diabetic conditions, as described by Ozdemir and Feinberg and others [6,21,26–28]. All phases of wound healing are affected by miRNAs and they have been shown to be altered in diabetes. Of special interest is the observation that specific sets of miRNAs are involved in acute and chronic inflammation ('inflammiRs'). These inflammiRs include miR-146a, miR-155, miR-15-b-5p, miR-132, miR-191

Abbreviations: miRNA, microRNA; DFU, diabetic foot ulcer.

* Corresponding author at.

E-mail addresses: ltid@ruc.dk (L.T. Dalgaard), ecarvalh@cnc.uc.pt (E. Carvalho).

and miR-200 family members, also important in wound healing, but this list is not exhaustive and more miRNAs are likely regulated by acute and/or chronic inflammation [29–31]. Because it is possible to improve diabetic wound healing by controlling skin inflammation [7] at least in mouse models, the obvious question is whether these miRNAs can be employed in an immune modulatory fashion to improve diabetic wound healing? In addition, miRNAs may work in clusters and not individually as many studies have so far evaluated. Furthermore, the notion that molecules work together in a concerted way to regulate processes, such as metabolism, cellular immunity, inflammation and wound repair is not new; however it is a new fact that exosomes, small extracellular vesicles, can regulate cell to cell cross-talk and all of these functions due to their specific cargo [32]. Exosomes have been used in wound healing, a promising new technology, that carry not only miRNAs but also small bioactive molecules, including peptides and proteins that together can better contribute to immunomodulation, inflammation and tissue repair [32–34].

Interestingly, new studies point to the regulation of miRNAs by host microbiota [35–37]. This could be important in DFU pathogenesis, because DFUs are colonized and a majority of chronic wounds are infected with pathogens [16]. Microbes extensively communicate with the host immune system and modulate host miRNA expression in the gut and brain, but how the microbial composition interacts with miRNA during wound healing is not well established. Data indicate that miRNAs, including miR-15b-5p, miR-146, miR-155, miR-125, and miR-21, can be affected during bacterial infection and may contribute to immune responses [38,39]. It is therefore intriguing to think that by manipulating wound local microbes one could potentiate healing via modulation of miRNA expression. In addition, another important idea that needs further investigation is the fact that bacterial small RNAs may significantly regulate human genes in ways that could alter host cellular processes involved in wound healing [40].

Furthermore, a major limitation of many studies concerning miRNA action in wound healing is the use of mouse models for wound healing. There are several important differences between wound healing in mice and humans: Mice heal by contraction of the epidermis, while human wounds close by granulation tissue [41]. The stem cell niches of mouse and human dermis are different, as well as both the normal and pathogenic microbiota. Moreover, the microbial composition of DFUs is highly heterogeneous [42,43], whereas mouse models by nature of being models are very homogenous, which may limit translatability. Although miRNAs are evolutionarily highly conserved, a primate specific miRNAs was described as having an important role in wound healing of human skin [44]. Thus, mice and humans may have different sets of miRNA involved in cutaneous wound healing. Even though miRNAs may be conserved in sequence and regulation between mouse and human skin, it is important to consider that the target mRNAs, upon which miRNAs act, are far less likely to be conserved [45]. Additionally, mouse wounds are for the most part acute wounds, while human DFUs are normally chronic wounds having persistent inflammation, and which do not follow the standard time course of cellular and molecular events that leads towards the healing of a healthy acute wound. Finally, healing of a DFU depends to a high degree of pressure off-loading. If the ulcer is sufficiently off-loaded, healing will often occur (although slowly), while the DFU under perpetual pressure will not heal. Mouse wound healing models are inadequate by not being under pressure. These limitations to the use of mice for wound healing studies also impede the identification of mechanisms important for human wound healing, and, in particular, healing of DFUs. Thus, studies should be performed in human skin models and in tissue or samples from diabetic patients in order to validate miRNA findings obtained in mice and translate these into useful clinical treatment.

References

- [1] Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 1999;341(10):738–46.
- [2] Sorg H, et al. Skin wound healing: an update on the current knowledge and concepts. *Eur Surg Res* 2017;58(1-2):81–94.
- [3] Eming SA, et al. Inflammation in wound repair: molecular and cellular mechanisms. *J Invest Dermatol* 2007;127(3):514–25.
- [4] Emanuelli T, et al. Effects of insulin on the skin: possible healing benefits for diabetic foot ulcers. *Arch Dermatol Res* 2016;308(10):677–94.
- [5] Tellechea A, et al. Mast cells regulate wound healing in diabetes. *Diabetes* 2016;65(7):2006–19.
- [6] Moura J, et al. The role of microRNAs in diabetic complications – special emphasis on wound healing. *Genes (Basel)* 2014;5(4):926–56.
- [7] Dhall S, et al. Generating and reversing chronic wounds in diabetic mice by manipulating wound redox parameters. *J Diabetes Res* 2014;2014:562625.
- [8] daSilva L, et al. Role of neuropeptides in skin inflammation and its involvement in diabetic wound healing. *Expert Opin Biol Ther* 2010;10(10):1427–39.
- [9] Falanga V. Wound healing and its impairment in the diabetic foot. *Lancet* 2005;366(9498):1736–43.
- [10] Leal EC, et al. Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. *Am J Pathol* 2015;185(6):1638–1648.
- [11] Tecilizach F, et al. Role of endothelial progenitor cells and inflammatory cytokines in healing of diabetic foot ulcers. *PLoS One* 2013;8(12):e83314.
- [12] Tellechea A, et al. Increased skin inflammation and blood vessel density in human and experimental diabetes. *Int J Low Extrem Wounds* 2013;12(1):4–11.
- [13] Zimmet PZ, Alberti KG. Epidemiology of diabetes – status of a pandemic and issues around metabolic surgery. *Diabetes Care* 2016;39(6):878–883.
- [14] Chen L, et al. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. *Nat Rev Endocrinol* 2011;8(4):228–36.
- [15] Whiting DR, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract* 2011;94(3):311–321.
- [16] Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27(5):1047–53.
- [17] Akhtar S, et al. A review of the Eurodiab studies: what lessons for diabetic foot care? *Curr Diab Rep* 2011;11(4):302–9.
- [18] Apelqvist J. Diagnostics and treatment of the diabetic foot. *Endocrine* 2012;41(3):384–97.
- [19] Boulton AJ, et al. The global burden of diabetic foot disease. *Lancet* 2005;366(9498):1719–24.
- [20] Almdal T, et al. Increased healing in diabetic toe ulcers in a multidisciplinary foot clinic – an observational cohort study. *Diabetes Res Clin Pract* 2015;110(3):315–21.
- [21] Ozdemir D, Feinberg MW. MicroRNAs in diabetic wound healing: pathophysiology and therapeutic opportunities. *Trends Cardiovasc. Med* 2018 [Epub ahead of print]. doi:10.1016/j.tcm.2018.08.002.
- [22] Roberts TC. The microRNA Machinery. *Adv Exp Med Biol* 2015;887:15–30.
- [23] Filipowicz W, Sonenberg N. The long unfinished march towards understanding microRNA-mediated repression. *RNA* 2015;21(4):519–24.
- [24] Krol J, et al. The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet* 2010;11(9):597–610.
- [25] Vienberg S, et al. MicroRNAs in metabolism. *Acta Physiol (Oxf)* 2017;219(2):346–61.
- [26] Zhang Y, et al. Emerging roles for microRNAs in diabetic microvascular disease: novel targets for therapy. *Endocr Rev* 2017;38(2):145–68.
- [27] van Solingen C, et al. Improved repair of dermal wounds in mice lacking microRNA-155. *J Cell Mol Med* 2014;18(6):1104–12.
- [28] Ojeh N, et al. The effects of caffeine on wound healing. *Int Wound J* 2016;13(5):605–13.
- [29] Fu L, et al. Comprehensive review of genetic association studies and meta-analysis on miRNA polymorphisms and rheumatoid arthritis and systemic lupus erythematosus susceptibility. *Hum Immunol* 2016;77(1):1–6.
- [30] Sastre B, et al. Novel modulators of asthma and allergy: exosomes and microRNAs. *Front Immunol* 2017;8:826.
- [31] Mann M, et al. An NF-kappaB-microRNA regulatory network tunes macrophage inflammatory responses. *Nat Commun* 2017;8(1):851.
- [32] Bui TM, et al. Extracellular vesicles regulate immune responses and cellular function in intestinal inflammation and repair. *Tissue Barriers* 2018:e1431038.
- [33] Hu L, et al. Exosomes derived from human adipose mesenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. *Sci Rep* 2016;6:32993.
- [34] Bakhtyar N, et al. Exosomes from acellular Wharton's jelly of the human umbilical cord promotes skin wound healing. *Stem Cell Res Ther* 2018;9(1):193.
- [35] Belcheva A. MicroRNAs at the epicenter of intestinal homeostasis. *Bioessays* 2017;39(3).
- [36] Hoban AE, et al. Microbial regulation of microRNA expression in the amygdala and prefrontal cortex. *Microbiome* 2017;5(1):102.
- [37] Maudet C, et al. MicroRNAs in the interaction between host and bacterial pathogens. *FEBS Lett* 2014;588(22):4140–7.
- [38] Staedel C, Darfeuille F. MicroRNAs and bacterial infection. *Cell Microbiol* 2013;15(9):1496–507.
- [39] Ramirez HA, et al. Staphylococcus aureus triggers induction of miR-15B-5P to

- diminish DNA repair and deregulate inflammatory response in diabetic foot ulcers. *J Invest Dermatol* 2018;138(5):1187–96.
- [40] Shmaryahu A, et al. Prediction of bacterial microRNAs and possible targets in human cell transcriptome. *J Microbiol* 2014;52(6):482–9.
- [41] Zomer HD, Trentin AG. Skin wound healing in humans and mice: challenges in translational research. *J Dermatol Sci* 2018;90(1):3–12.
- [42] Bjarnsholt T, et al. Why chronic wounds will not heal: a novel hypothesis. *Wound Repair Regen* 2008;16(1):2–10.
- [43] Thomsen TR, et al. The bacteriology of chronic venous leg ulcer examined by culture-independent molecular methods. *Wound Repair Regen* 2010;18(1):38–49.
- [44] Sundaram GM, et al. 'See-saw' expression of microRNA-198 and FSTL1 from a single transcript in wound healing. *Nature* 2013;495(7439):103–6.
- [45] Witkos TM, et al. Practical aspects of microRNA target prediction. *Curr Mol Med* 2011;11:93–109.